EWING, NJ--(Marketwire - April 29, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or “The Company”), a late-stage biopharmaceutical company, announced today the initiation of a comprehensive program to evaluate the efficacy of RiVax™ in non-human primates. RiVax™ is a recombinant subunit vaccine intended to protect humans against exposure to ricin toxin. The program, funded in large part by the National Institute of Allergy and Infectious Diseases (NIAID), is intended to supply efficacy data for RiVax™ in vaccinated rhesus monkeys (macaques) and to develop correlates of immunity. These data will further aid in interpretation of immunogenicity data obtained in human vaccination trials. The studies will take place at Tulane National Primate Research Center, a part of the Tulane University Health Sciences Center.
